BYSI - Additional data show BeyondSpring' plinabulin at par with Amgen' pegfilgrastim

BeyondSpring ([[BYSI]] -0.6%) has announced new data on its lead drug plinabulin, demonstrating it to be a favorable option for preventing chemo-induced neutropenia ((CIN)) during the pandemic, compared to Amgen's Neulasta (pegfilgrastim, Peg), long-lasting G-CSF.In terms of severe neutropenia (low levels of white blood cells called neutrophils), plinabulin as a single agent was equally effective as peg., in preventing hospitalizations, infections and sepsis.Though when it came to thrombocytopenia and bone pain, Plinabulin demonstrated advantages over peg.The company has started an U.S. Expanded Access Program to enable doctors, for use of Plinabulin both alone and in combination with G-CSFs, during the pandemic.

For further details see:

Additional data show BeyondSpring' plinabulin at par with Amgen' pegfilgrastim